7. Survival analysis
The median follow-up duration was 38.7 months (range: 2.7-317.6 months).
41 (57.7%) patients died during
follow-up.
5-year OS for the entire cohort was 52.9% (Figure S1). Stage-specific
5-year OS were as follows: stage I—60.7%, stage II-IV—27.8%
(P=0.001; Figure S2). Patients
experienced first recurrence after
initial diagnoses within 12 months had a worse 5-year OS than those
after 12 months (17.0% vs 69.1%, P<0.001, Figure 1A). 5-year
OS for the SCS and non-SCS subgroup was 62.0% and 28.0%, respectively
(P<0.001; Figure S3). Patients who
recurred at isolated site associated
had a better survival (5-year OS: 73.5% vs 44.0%, P=0.045; Figure S4).
Patients who developed recurrence in multiple locations had a
significantly worse survival (5-year OS: 58.4% vs 34.7% P=0.039,
Figure 2).
Of the 52 patients undergoing SCS, patients experienced first recurrence
after initial diagnoses within 12
months had a worse 5-year OS than those after 12 months (28.5% vs
72.8%, P=0.001, Figure 1B). Patients with residual tumors after
cytoreductive surgery had a tendency towards a worse survival than those
without (5-year OS: 20.0% vs 67.7%, P=0.082; Figure S5). Patients who
received non-genital organ surgeries had a non-significantly worse
survival than those who did not
receive (5-year OS: 51.5% vs 69.8%, P=0.057; Figure S6). And patients
with lung-only recurrence (n=10) had a tendency towards better 5-year OS
than those without (n=42) (77.8%% vs 57.8%, P=0.938; Figure S7).
Multivariate analysis showed time to
fist recurrence within 12 months (HR=4.60, 95% CI: 1.49-14.4, P =
0.008, Table 5) was an independent predictor of decreased 5-year OS
after adjusted time to fist recurrence, diameter of largest mass found
at SCS, isolated site recurrence, multiple locations, non-genital organ
surgeries, residual tumor, adjuvant chemotherapy.